Now I want to hear from you: Are you someone who has taken or is currently taking a GLP-1 agonist
If in fact future studies robustly establish a beneficial effect of the drug class in HF, it may allow for broader adoption of GLP-1 RAs in the prevalent CVD, ultimately contributing to addressing the unmet medical need that continues to persist in the prevention or management of, in particular, HFpEF
Animal models show that GLP-1 drugs improve memory, reduce neural apoptosis, and increase synaptic density
Patients can expect to lose between 15-20% of their body weight over the course of 12 months, especially when combined with other weight loss efforts
The differences seen by income groups may be influenced by both the increased use of GLP-1 RAs during the study period (Rodriguez et al., 2023) and the change in clinical guidelines during the period (Summary of Revisions, 2020)
Am J Obstet Gynecol (1995) 173(3 Pt 1):7607